Matches in SemOpenAlex for { <https://semopenalex.org/work/W3150614234> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3150614234 endingPage "118" @default.
- W3150614234 startingPage "112" @default.
- W3150614234 abstract "AIM:To assess the relative bioavailability and pharmacokinetic properties of two formulations(test and reference) of Lafutidine 10 mg.METHODS:The study was performed as an open label,randomized,two-way,two-period,two-treatment,single dose cross-over bioequivalence study,under non-fed condition to compare the pharmacokinetic prof iles of the lafutidine formulation manufactured by Emcure Pharmaceuticals Ltd.,India using an indigenously developed active pharmaceutical ingredient(API) and the commercially available Stogra formulation,of UCB Japan Co.,Ltd.,Japan.The two treatments were separated by a washout period of 5 d.After an overnight fasting period of 10 h,the subjects were administered either the test or the reference medication as per the randomization schedule.Blood samples were collected at intervals up to 24 h,as per the approved protocol.Concentrations of lafutidine in plasma were analyzed by a validated liquid chromatography/tandem mass spectrometry(LC/MS/MS) method,and a non-compartmental model was used for pharmacokinetic analysis.The pharmacokinetic parameters were subjected to a 4-way ANOVA accounting for sequence,subjects,period and treatment.Statistical significance was evaluated at 95% conf idence level(P ≥ 0.05).RESULTS:The mean(±SD) values of the pharmacokinetic parameters(test vs reference) were Cmax(265.15±49.84 ng/mL vs 246.79±29.30 ng/mL,P<0.05),Area under the curve(AUC)(0-t)(1033.13±298.74 ng.h/mL vs 952.93±244.07 ng.h/mL,P < 0.05),AUC(0-∞)(1047.61±301.22 ng.h/mL vs 964.21±246.45 ng.h/mL,P<0.05),and tv2(1.92±0.94 h vs 2.05±1.01 h,P<0.05).The 90% conf idence intervals(CI) for the test/reference ratio of mean Cmax,AUC(0-t),and AUC(0-∞) were within the acceptable range of 80.00 to 125.00.The mean times(± SD) to attain maximal plasma concentration(tmax) of lafutidine were 0.95±0.24 h vs 1.01±0.29 h(P<0.05) for the test and the reference formulations respectively.Both the formulations were well tolerated." @default.
- W3150614234 created "2021-04-13" @default.
- W3150614234 creator A5012949434 @default.
- W3150614234 creator A5059916417 @default.
- W3150614234 creator A5073086894 @default.
- W3150614234 creator A5087574894 @default.
- W3150614234 date "2010-01-01" @default.
- W3150614234 modified "2023-09-23" @default.
- W3150614234 title "An open-label,randomized,cross-over bioequivalence study of lafutidine 10 mg under fasting condition" @default.
- W3150614234 hasPublicationYear "2010" @default.
- W3150614234 type Work @default.
- W3150614234 sameAs 3150614234 @default.
- W3150614234 citedByCount "0" @default.
- W3150614234 crossrefType "journal-article" @default.
- W3150614234 hasAuthorship W3150614234A5012949434 @default.
- W3150614234 hasAuthorship W3150614234A5059916417 @default.
- W3150614234 hasAuthorship W3150614234A5073086894 @default.
- W3150614234 hasAuthorship W3150614234A5087574894 @default.
- W3150614234 hasConcept C112705442 @default.
- W3150614234 hasConcept C126322002 @default.
- W3150614234 hasConcept C142724271 @default.
- W3150614234 hasConcept C168563851 @default.
- W3150614234 hasConcept C181389837 @default.
- W3150614234 hasConcept C204243189 @default.
- W3150614234 hasConcept C204787440 @default.
- W3150614234 hasConcept C22979827 @default.
- W3150614234 hasConcept C27081682 @default.
- W3150614234 hasConcept C42404028 @default.
- W3150614234 hasConcept C71924100 @default.
- W3150614234 hasConcept C87813604 @default.
- W3150614234 hasConcept C98274493 @default.
- W3150614234 hasConceptScore W3150614234C112705442 @default.
- W3150614234 hasConceptScore W3150614234C126322002 @default.
- W3150614234 hasConceptScore W3150614234C142724271 @default.
- W3150614234 hasConceptScore W3150614234C168563851 @default.
- W3150614234 hasConceptScore W3150614234C181389837 @default.
- W3150614234 hasConceptScore W3150614234C204243189 @default.
- W3150614234 hasConceptScore W3150614234C204787440 @default.
- W3150614234 hasConceptScore W3150614234C22979827 @default.
- W3150614234 hasConceptScore W3150614234C27081682 @default.
- W3150614234 hasConceptScore W3150614234C42404028 @default.
- W3150614234 hasConceptScore W3150614234C71924100 @default.
- W3150614234 hasConceptScore W3150614234C87813604 @default.
- W3150614234 hasConceptScore W3150614234C98274493 @default.
- W3150614234 hasIssue "5" @default.
- W3150614234 hasLocation W31506142341 @default.
- W3150614234 hasOpenAccess W3150614234 @default.
- W3150614234 hasPrimaryLocation W31506142341 @default.
- W3150614234 hasRelatedWork W1462905453 @default.
- W3150614234 hasRelatedWork W1557970932 @default.
- W3150614234 hasRelatedWork W2007355272 @default.
- W3150614234 hasRelatedWork W2034127399 @default.
- W3150614234 hasRelatedWork W2045135299 @default.
- W3150614234 hasRelatedWork W2073314680 @default.
- W3150614234 hasRelatedWork W2094529680 @default.
- W3150614234 hasRelatedWork W2151863940 @default.
- W3150614234 hasRelatedWork W2187067230 @default.
- W3150614234 hasRelatedWork W2316563254 @default.
- W3150614234 hasRelatedWork W2323769782 @default.
- W3150614234 hasRelatedWork W2357125785 @default.
- W3150614234 hasRelatedWork W2364317128 @default.
- W3150614234 hasRelatedWork W2371360730 @default.
- W3150614234 hasRelatedWork W2585288183 @default.
- W3150614234 hasRelatedWork W2601835201 @default.
- W3150614234 hasRelatedWork W2809704462 @default.
- W3150614234 hasRelatedWork W3084300720 @default.
- W3150614234 hasRelatedWork W3098355829 @default.
- W3150614234 hasRelatedWork W2185795336 @default.
- W3150614234 isParatext "false" @default.
- W3150614234 isRetracted "false" @default.
- W3150614234 magId "3150614234" @default.
- W3150614234 workType "article" @default.